Sechium edule extract for diabetic nephropathy research and therapeutic development

Overview

Diabetic nephropathy (DN) is a major long-term complication of diabetes mellitus, developing in more than 40% of patients even with glucose control, and remains the most common cause of end-stage renal disease. This research program investigates the therapeutic potential of Sechium edule (chayote) fruit extracts as a natural intervention for diabetic nephropathy. The program builds on preliminary findings demonstrating nephroprotective and antidiabetic activity of Sechium edule, with the goal of validating its effects on renal function, inflammatory markers, and kidney tissue pathology in validated animal models.

Technical specifications

Research approach:

• Uses streptozotocin-high fat diet (STZ-HFD) induced diabetic nephropathy model in Wistar rats
• Ethanolic extracts of Sechium edule fruits administered orally at 100 mg/kg and 200 mg/kg doses
• Glibenclamide (5 mg/kg) used as reference antidiabetic agent
• Treatment duration of up to 60 days with high-fat diet maintenance

Validated preliminary findings:

• Prevention of body weight loss in diabetic rats
• Significant reduction (P<0.01) in blood glucose levels at days 0, 7, 14, and 21
• Improved lipid profile in diabetic rats following extract administration

Planned validation assessments:

• Kidney function test biochemical estimations
• Serum and kidney-level inflammatory marker quantification
• mRNA expression analysis of inflammatory mediators
• Kidney histology and transmission electron microscopy (TEM)
• Assessment of glycated hemoglobin and VEGF involvement in DN pathogenesis

Technology readiness level

This research is at the preclinical validation stage (TRL 3-4). Preliminary antidiabetic and nephroprotective activities of Sechium edule have been established in alloxan-induced diabetic rat models. The program is now advancing to a more clinically relevant STZ-HFD induced diabetic nephropathy model with comprehensive biochemical, molecular, and histopathological endpoints. The research is positioned to generate translational data supporting potential development of a natural product-based therapeutic intervention for diabetic kidney disease.